Prevalence of clinically significant prostate carcinoma in Prostate Imaging Reporting and Data System (PIRADS) 3 lesions detected in the peripheral zone on biparametric magnetic resonance imaging (MRI)—a local experience
Clinical Radiology · 2024
DOI: 10.1016/j.crad.2024.07.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Radiology, 2024. Verfasst von M J Khalid und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Hull University Teaching Hospitals NHS Trust, Kingston-upon-Hull, UK. Electronic address: muhammadj.khalid@nhs.net. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
AIM: The aim of this study was to determine whether biparametric magnetic resonance imaging (MRI) is effective in the diagnosis of clinically significant prostate cancer in prostate peripheral zone Prostate Imaging Reporting and Data System (PIRADS) 3 lesions without the use of dynamic contrast enhancement. MATERIALS AND METHODS: Patients who underwent biparametric MRI over a 12-month period from January 2022 to December 2022 and were diagnosed with PIRADS 3 lesion in the peripheral zone were included in the study. No patient received dynamic contrast enhancement. Histological analysis was done after performing local anesthetic transperineal biopsy to determine detection rate of clinically significant prostate cancer. Prostate-specific antigen density (PSAD) and biopsy complication rates were also reviewed. RESULTS: Sixty-one out of 688 MRIs (8.8%) performed over the study period had a PIRADS 3 lesion in the peripheral zone where contrast is supposed to add value. Fifty-eight of the 61 went ahead to biopsy, and csPCa (Gleason score: ≥3 + 4, with a max core length of ≥6 mm and above) was diagnosed in 17%. Among those diagnosed with csPCa, 80% had a PSAD of >0.15 ng/ml/cc. No postbiopsy complications were reported. CONCLUSION: Biparametric MRI without contrast offers a reliable alternative to multiparametric MRI with minimum or neglible impact on clinically significant prostate cancer (csPCa) diagnosis in peripheral zone PIRADS 3 lesions, especially when used in conjunction with other factors such as PSAD. There is potential to address health economics and patient burden in prostate cancer investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiology, Hull University Teaching Hospitals NHS Trust, Kingston-upon-Hull, UK. Electronic address: muhammadj.khalid@nhs.net.
- Department of Radiology, Hull University Teaching Hospitals NHS Trust, Kingston-upon-Hull, UK.
Zitieren
APA
Khalid, M. J., Parker, P., Smith, S., Byass, O. R., & Cast, J. E. I. (2024). Prevalence of clinically significant prostate carcinoma in Prostate Imaging Reporting and Data System (PIRADS) 3 lesions detected in the peripheral zone on biparametric magnetic resonance imaging (MRI)—a local experience. Clinical Radiology. https://doi.org/10.1016/j.crad.2024.07.014
Vancouver
Khalid MJ, Parker P, Smith S, Byass OR, Cast JEI. Prevalence of clinically significant prostate carcinoma in Prostate Imaging Reporting and Data System (PIRADS) 3 lesions detected in the peripheral zone on biparametric magnetic resonance imaging (MRI)—a local experience. Clinical Radiology. 2024. doi:10.1016/j.crad.2024.07.014
BibTeX
@article{Khalid2024,
author = {Khalid, M J and Parker, P and Smith, S and Byass, O R and Cast, J E I},
title = {Prevalence of clinically significant prostate carcinoma in Prostate Imaging Reporting and Data System (PIRADS) 3 lesions detected in the peripheral zone on biparametric magnetic resonance imaging (MRI)—a local experience},
journal = {Clinical Radiology},
year = {2024},
doi = {10.1016/j.crad.2024.07.014}
}
EUVIMED